Article Text
Statistics from Altmetric.com
Commentary on: Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019:CD007076. doi: 10.1002/14651858.CD007076.pub3.
Implications for practice and research
There is moderate quality evidence that pregabalin is more effective than placebo for postherpetic neuralgia, painful diabetic neuropathy and post-traumatic neuropathic pain.
There is no evidence to support its use in HIV neuropathy nor central neuropathic pain.
Future studies require greater sample sizes and clearer methodology.
There is a need to identify patients who would benefit from pregabalin therapy.
Context
Pregabalin is licensed to treat neuropathic pain which is defined as pain caused by a lesion or disease of the somatosensory nervous system.1 Neuropathic pain effects up to 10% of the population2 and includes postherpetic neuralgia (PHN) and painful diabetic neuropathy (PDN). The …
Footnotes
Competing interests I have acted as a speaker for Pfizer for which I have received payment.
Provenance and peer review Commissioned; internally peer reviewed.